drugset
drugset / Trial / NCT04242953

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects

NCT04242953 ↗

Phase 1 Completed 140 enrolled Sun Pharma Advanced Research Company Limited
RandomizedParallel-groupTriple-blindOther

Summary

This is a Multipart Phase 1 Randomized, Double blind and Placebo controlled Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in healthy male and postmenopausal female volunteers.

Timeline

Start
2020-03-04
Primary completion
2022-10-21
Completion
2022-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject SCO-120 Unknown — Oral

Indications

No indication recorded.